Trials / Conditions / Primary Immunodeficiency Diseases (PID)

Primary Immunodeficiency Diseases (PID)

25 registered clinical trials studyying Primary Immunodeficiency Diseases (PID) — 5 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Efficacy, Safety and Pharmacokinetic of Virchow IVIG in PID Patients NCT07017036	Virchow Group	Phase 3
Recruiting	A Database Survey to Evaluate the Safety of Immune Globulin Subcutaneous (Human), 20% Solution in Participants NCT06565078	Takeda	—
Not Yet Recruiting	Inbon Errors of Immunity Attending Assiut University Children&Amp;#39;s Hospital: a Single Center Study NCT06649643	Assiut University	—
Recruiting	Ex Vivo Evaluation of JAK-inhibitor and Gene Therapeutical Approach in JAK-STAT Related Disorders NCT07261891	prof. dr. Rik Schrijvers	N/A
Active Not Recruiting	A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases NCT06076642	Takeda	Phase 3
Recruiting	Virtual Reality on Pain and Fear Levels of Children With Primary Immunodeficiency NCT07004803	Dr. Hatice Dönmez	N/A
Completed	At-Home Subcutaneous Immunoglobulin Replacement Therapy Using Alexa Skill NCT06150534	Takeda	—
Completed	A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Di NCT05755035	Takeda	Phase 2 / Phase 3
Completed	A Study to Evaluate the Long-term Safety of TAK-771 in Japanese Primary Immunodeficiency Disease (PID) Partici NCT05513586	Takeda	Phase 3
Unknown	Evaluation of Subcutaneous Immunoglobulin Product Cutaquig in Terms of Safety and Efficacy in the Treatment of NCT05986734	Federal Research Institute of Pediatric Hematology, Oncology and Immunology	—
Completed	A Study of TAK-771 in Japanese People With Primary Immunodeficiency Diseases (PID) NCT05150340	Takeda	Phase 3
Completed	A Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) in Japanese Participants With Primar NCT04346108	Baxalta now part of Shire	Phase 3
Completed	Real-world CANadian CUvitru Non-Interventional Study in Subjects Transitioning From Subcutaneous Immunoglobuli NCT03716700	Baxalta now part of Shire	—
Completed	Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric PIDD Subj NCT03277313	Baxalta now part of Shire	Phase 3
Completed	Post-Authorization Safety, Tolerability and Immunogenicity Evaluation of HyQvia in Pediatric PIDD Subjects NCT03116347	Baxalta now part of Shire	Phase 4
Completed	Non-Interventional Post-Marketing Safety Study on the Long-Term Safety of HYQVIA (Global) NCT02593188	Baxalta now part of Shire	—
Completed	Phase 2/3 Study of IGSC, 20% in PIDD NCT01218438	Baxalta now part of Shire	Phase 2 / Phase 3
Completed	Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD NCT01485796	Baxalta now part of Shire	Phase 2 / Phase 3
Completed	Immune Globulin Subcutaenous (Human), 20% NCT01412385	Baxalta now part of Shire	Phase 2 / Phase 3
Completed	Tolerability and Safety of Immune Globulin Subcutaneous Solution (IGSC) and rHuPH20 in PID NCT01175213	Baxalta now part of Shire	Phase 3
Completed	Gammagard Liquid and rHuPH20 in PID NCT00814320	Baxalta now part of Shire	Phase 3
Completed	Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subje NCT00546871	Baxalta now part of Shire	Phase 2 / Phase 3
Completed	Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneo NCT00782106	Baxalta now part of Shire	Phase 1 / Phase 2
Completed	Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficie NCT00157079	Baxalta now part of Shire	Phase 3
Completed	Safety, Pharmacokinetic and Efficacy Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solutio NCT00161993	Baxalta now part of Shire	Phase 2